Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
McKinsey
Covington
Fuji
Fish and Richardson
Harvard Business School
Boehringer Ingelheim
US Department of Justice
Farmers Insurance
Express Scripts

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,358,527

« Back to Dashboard

Which drugs does patent 6,358,527 protect, and when does it expire?

Patent 6,358,527 protects RAZADYNE and is included in one NDA.

This patent has forty-two patent family members in thirty-three countries.
Summary for Patent: 6,358,527
Title: Fast-dissolving galanthamine hydrobromide tablet
Abstract:The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.
Inventor(s): Gilis; Paul Marie Victor (Beerse, BE), De Conde ; Valentin Florent Victor (Lommel, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:09/585,122
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 6,358,527

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-001 Feb 28, 2001 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF ALZHEIMER'S DEMENTIA ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 AB RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF ALZHEIMER'S DEMENTIA ➤ Subscribe
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-003 Feb 28, 2001 AB RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF ALZHEIMER'S DEMENTIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,358,527

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
96201676Jun 14, 1996

Non-Orange Book US Patents Family Members for Patent 6,358,527

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,099,863 Fast-dissolving galanthamine hydrobromide tablet ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,358,527

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong 1019703 ➤ Subscribe
Croatia P970321 ➤ Subscribe
Hungary 9903476 ➤ Subscribe
Hungary 226132 ➤ Subscribe
Indonesia 17088 ➤ Subscribe
Israel 127519 ➤ Subscribe
Japan 2000511918 ➤ Subscribe
Japan 4172820 ➤ Subscribe
South Korea 100358676 ➤ Subscribe
South Korea 20000015851 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Harvard Business School
Colorcon
Fuji
Chubb
US Department of Justice
McKesson
Fish and Richardson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot